PBM Prosecution May Rely On Adverse Event From Rx Switch - FDLI Panel

A serious adverse event associated with a therapeutic switch may be the trigger for a case to emerge from the ongoing Philadelphia grand jury investigation of PBM practices, panelists suggested during a Food & Drug Law Institute/Health Care Compliance Association meeting in Washington, D.C. Oct. 18.